August 7, 2024 02:51 PM EDT
Pharma
FDA+

FDA rep­ri­mands Bris­tol My­ers over mis­lead­ing ef­fi­ca­cy claims on Kraza­ti web­site

Katherine Lewin

News Reporter

The FDA told Bris­tol My­ers Squibb in an Aug. 1 let­ter that a web­site for its can­cer drug Kraza­ti had mis­lead­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Roche, Genen­tech end an­ti-tau Alzheimer’s drug col­lab­o­ra­tion with UCB

Aven­Cell gets $112M to build switch­able CAR-T ther­a­pies for ‘the last fron­tier’ of blood can­cers

FDA hits Ca­mu­rus with CRL for acromegaly ther­a­py over man­u­fac­tur­ing is­sues 

Q3 biotech roundup: The 2024 turn­around sput­ters in­to a crit­i­cal Q4 fi­nale

Star­board takes ac­tivist stake in J&J con­sumer spin­out Ken­vue

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times